InsidersTradesSigma
CytoDyn Inc.: management transactions · United States · SEC (Form 4)
SEC:cytodyn-inc-30373aUS·SEC (Form 4)Mcap 472M€Healthcare & Pharma
Browse the full insider trade history of CytoDyn Inc., a listed equity based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, CytoDyn Inc. has logged 19 insider filings. Market capitalisation: €471.7m. The latest transaction was reported on 21 June 2022 (Attribution). Among the most active insiders: Ray Nitya G.. Every trade is free.
19
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
0.34 €
Analyst consensus
Valuation
Beta1.15
Profitability & ownership
ROA-67.4%
% insiders0.0%
% institutions0.0%
Last declaration on 21 June 2022
Declarations19 total
Executives◆Grant12SEC
013,671 shares0
Common Stock
SEC:0001104659-22-073013:0·
Executives◆Grant20SEC
010,807 shares0
Common Stock
SEC:0001104659-22-073010:0·
Executives◆Grant12SEC
014,780 shares0
Common Stock
SEC:0001104659-22-069303:0·
Executives◆Grant20SEC
011,683 shares0
Common Stock
SEC:0001104659-22-069294:0·
Executives◆Grant3SEC
012,950 shares0
Common Stock
SEC:0001104659-22-069300:0·
Executives◇Options17SEC
€340,708888,888 shares@ €0.3833100.0% of flow
Common Stock
SEC:0000899243-21-037904·
Executives◇Options23SEC
€340,708888,888 shares@ €0.38330.072% mcap50.0% of flow
Common Stock
SEC:0000899243-21-037904:0·
Executives◆Grant13SEC
03,023 shares0
Common stock
SEC:0000899243-21-032387·
Executives◆Grant9SEC
034,801 shares0
Common stock
SEC:0000899243-21-032389·
Executives◆Grant9SEC
019,384 shares0
Common stock
SEC:0000899243-21-032385·
Executives◆Grant14SEC
075,758 shares0
Common stock
SEC:0000899243-21-032402·
Executives◆Grant9SEC
040,661 shares0
Common stock
SEC:0000899243-21-032395·
Executives◆Grant12SEC
034,801 shares0
Common stock
SEC:0000899243-21-032389:0·
Executives◆Grant12SEC
019,384 shares0
Common stock
SEC:0000899243-21-032385:0·
Executives◆Grant20SEC
03,023 shares0
Common stock
SEC:0000899243-21-032387:0·
Executives◆Grant23SEC
075,758 shares0
Common stock
SEC:0000899243-21-032402:0·
Executives◆Grant12SEC
040,661 shares0
Common stock
SEC:0000899243-21-032395:0·
19 of 19 declarations
About CytoDyn Inc.
Geographically, CytoDyn operates primarily from the United States and maintains its headquarters in Vancouver, Washington. The company’s development work is centered on U.S. clinical and regulatory pathways, with academic collaborations involving U.S. research institutions. Recent milestones matter for market perception: new oncology data were presented in 2026, an investor webcast was held on April 30, 2026, and the company publicly discussed ongoing phase 2 colorectal cancer work and planned phase 2 mTNBC activity. For investors in France, Belgium, and Switzerland, CytoDyn should be viewed as a speculative clinical-stage biotech with a single dominant scientific thesis, significant upside optionality if its CCR5/leronlimab program succeeds, and substantial execution risk if clinical or regulatory readouts disappoint.
